# Phase 1 Lymphoma, Large B-Cell, Diffuse trials: 52 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials in phase 1 for Lymphoma, Large B-Cell, Diffuse that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lymphoma, Large B-Cell, Diffuse trials: 52 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma-large-b-cell-diffuse

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07906080 | Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK\_D332) in Combination With Tafasitamab and... | Istituto Oncologico Veneto IRCCS | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906080) |
| October 21, 2026 | NCT07887646 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell... | BeOne Medicines | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, B-cell Malignancies | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887646) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 19, 2026 | NCT07881211 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell... | BeOne Medicines | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881211) |
| July 27, 2026 | NCT07729397 | Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma | The Methodist Hospital Research Institute | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729397) |
| July 24, 2026 | NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Weill Medical College of Cornell University | Phase 1 | Recruiting | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725406) |
| July 20, 2026 | NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | Jonsson Comprehensive Cancer Center | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714421) |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| June 30, 2026 | NCT07676877 | Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676877) |
| June 16, 2026 | NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | National Cancer Institute (NCI) | Phase 1 | Recruiting | AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649304) |
| June 10, 2026 | NCT07638982 | Axatilimab + CAR-T for High-Risk Lymphoma | Northside Hospital, Inc. | Phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell... | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638982) |
| May 13, 2026 | NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | Chipscreen Biosciences, Ltd. | Phase 1 | Not yet recruiting | Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma, Diffuse Large B-Cell Lymphoma... | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583771) |
| April 20, 2026 | NCT07539688 | Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Inert B-cell Lymphoma Transformed Into Large B-cell... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539688) |
| April 14, 2026 | NCT07528352 | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | University of Utah | Phase 1 | Recruiting | Diffuse Large B Cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528352) |
| March 18, 2026 | NCT07478848 | Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma... | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478848) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| January 26, 2026 | NCT07368270 | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Diffuse Large B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368270) |
| December 3, 2025 | NCT07260812 | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | TCRx Therapeutics Co.Ltd | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260812) |
| November 12, 2025 | NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226843) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| September 29, 2025 | NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Recruiting | Solid Tumors, Hematologic Malignancies | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195916) |
| August 3, 2025 | NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF\_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell... | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101328) |
| June 17, 2025 | NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | Peking University Cancer Hospital & Institute | Phase 1 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma, Mantle... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024147) |
| May 18, 2025 | NCT06977711 | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma... | The University of Texas Health Science Center at San Antonio | Phase 1 | Recruiting | Diffuse Large B-cell Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06977711) |
| March 5, 2025 | NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory... | City of Hope Medical Center | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859008) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Nurix Therapeutics, Inc. | 3 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 2 |
| University of Utah | 2 |
| City of Hope Medical Center | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Fudan University | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| TCRx Therapeutics Co.Ltd | 1 |
| Medical College of Wisconsin | 1 |
| [Chipscreen Biosciences, Ltd.](https://specstream.ai/data/clinical-trials/company/chipscreen-biosciences-ltd) | 1 |
| Zumutor Biologics Inc. | 1 |
| Mayo Clinic | 1 |
| Beijing Yongtai Ruike Biotechnology Company Ltd | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Istituto Oncologico Veneto IRCCS | 1 |
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 1 |
| Aurigene Discovery Technologies Limited | 1 |
| Northside Hospital, Inc. | 1 |
| The University of Texas Health Science Center at San Antonio | 1 |
| AIDS Malignancy Consortium | 1 |
| The Methodist Hospital Research Institute | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Verismo Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 36 |
| China | 9 |
| Italy | 7 |
| Australia | 5 |
| Spain | 5 |
| United Kingdom | 4 |
| France | 4 |
| Poland | 4 |
| Canada | 3 |
| Germany | 3 |
| Denmark | 2 |
| Japan | 2 |
| Belgium | 1 |
| India | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [Barbecue restaurants in the United States](https://specstream.ai/data/businesses/barbecue-restaurants/united-states)
- [Cement suppliers in the United States](https://specstream.ai/data/businesses/cement-suppliers/united-states)
- [Debt relief companies in the United States](https://specstream.ai/data/businesses/debt-relief-companies/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
